Objective-Increased levels of lipoprotein(a) are a highly heritable risk factor for coronary artery disease (CAD). The genetic determinants of lipoprotein(a) levels are mainly because of genetic variation in the apolipoprotein(a) gene (LPA). We have tested the association of a relatively common null allele of LPA with lipoprotein(a) levels and CAD risk in a large case-control cohort. We have also examined how null allele genotyping complements apolipoprotein(a) isoform typing to refine the relationship between LPA isoform size and circulating lipoprotein(a) levels. Approach and Results-The LPA null allele (rs41272114) was genotyped in the PROCARDIS (Precocious Coronary Artery Disease) case-control cohort (4073 CAD cases and 4225 controls). Lipoprotein(a) levels were measured in 909 CAD cases and 922 controls; apolipoprotein(a) isoform size was estimated using sodium dodecyl sulfate-agarose gel electrophoresis and a high-throughput quantitative polymerase chain reaction-based method. Null carriers are common (null allele frequency, 3%) and have significantly lower circulating lipoprotein(a) levels (P=2.1×10 −10 ) and reduced CAD risk (odds ratio, 0.79 [0.66-0.97]; P=0.023) compared with noncarriers. An additive allelic model of apolipoprotein(a) isoform size, refined by null allele genotype and quantitative polymerase chain reaction values, showed a sigmoid relationship with lipoprotein(a) levels, with baseline levels for longer isoform alleles and progressively higher levels of lipoprotein(a) for shorter isoform alleles.
L ipoprotein(a) is a complex lipoprotein particle found in the circulation of higher primates. It comprises a lowdensity lipoprotein-like particle with the addition of an apolipoprotein(a) molecule covalently bonded to apolipoprotein B. 1 In humans, increased lipoprotein(a) levels in the blood have been associated with increased risk of cardiovascular disease. [2] [3] [4] [5] Lipoprotein(a) levels vary substantially among individuals within a population, are uncorrelated with classic risk factors, and remain relatively constant throughout an individual's lifespan. 6 A large proportion of lipoprotein(a) level variation is inherited and is mainly attributed to genetic variation within the LPA gene that encodes apolipoprotein(a), the characteristic protein moiety of the particle. 7 Genetic variation in the LPA gene is defined by a repetitive genomic region harboring 2 exons encoding one of the kringle domains (kringle IV [KIV]-2) in apolipoprotein(a), resulting in a highly polymorphic protein that includes multiple copies of the kringle domain ranging in number from 3 to >40. 8 This variation has been proposed to directly affect circulating lipoprotein(a) levels by influencing the processing and secretion of apolipoprotein(a) isoforms from producing hepatocytes 9, 10 The copy number of KIV-2 repeats is inversely related to levels with larger molecules, hindering efficient secretion and resulting in lower circulating lipoprotein(a) levels. 5 Depending on the population studied, a significant proportion of the genetic variation attributed to the LPA gene is independent of the copy number variation (CNV). 11 This is consistent with the observation that isoforms of the same size differ widely in concentration, suggesting that variation in the number of kringle domains is not the only important LPA contributor to lipoprotein(a) quantitative variation. There are reports of single nucleotide polymorphisms (SNPs) associated with lipoprotein(a) levels, which either serve as proxy (tagging) markers for the CNV 5 or have no proven direct functional role or tagging association, such as the pentanucleotide repeat in the LPA promoter. 12 SNP rs41272114 is a functional polymorphism that results in alternative splicing and a prematurely terminated protein molecule that lacks the domain that is normally covalently linked to apolipoprotein B and is unable to form a mature lipoprotein(a) particle. 13 The functional effect of this relative common SNP, commonly referred to as a null allele, on circulating lipoprotein(a) levels has been found to be significant. 13 However, this SNP has not been included in any of the widely used commercial high-throughput SNP arrays and thus has not been examined in the large-scale genetic epidemiological studies that have highlighted the role of lipoprotein(a) as an independent risk factor for coronary artery disease (CAD), 5,14-16 ischemic stroke, 17 and other atherosclerotic diseases. 18 The main aim of the present study was to evaluate the effect of the LPA null allele on circulating lipoprotein(a) levels and CAD risk in PROCARDIS (Precocious Coronary Artery Disease), a European CAD case-control cohort. A second aim was to refine the relationship between apolipoprotein(a)/LPA isoform size/CNV copy number and lipoprotein(a) levels by combining null allele genotyping with kringle isoform typing based on immunoblotting and genomic methods.
Material and Methods
Materials and Methods are available in the online-only Supplement.
Results

LPA Null Allele in the PROCARDIS Study: Effect on Circulating Lipoprotein(a) Levels and Association With CAD Risk.
In the PROCARDIS cohort, minor allele frequency of the null rs41272114 SNP was 0.03, and genotype frequencies were within Hardy-Weinberg equilibrium (χ 2 =0.58; 1 df; P=0.44). Lipoprotein(a) levels were measured in 2000 individuals with a mean concentration of 21.6 mg/dL (SD, 24.6; median, 11.5 mg/dL; interquartile range, 6.03-27.7 mg/dL). After excluding individuals with missing genotypes, data were available for 1831 individuals (909 cases and 922 controls). The distribution of lipoprotein(a) levels in LPA null carriers and noncarriers is shown in Figure 1 and the Table. There was a significant association between circulating lipoprotein(a) levels and LPA null carrier status (P=2.1×10 −10 ) with a 5.25 mg/dL (95% confidence interval [CI], 3.75-6.75) reduction in median lipoprotein(a) levels in carriers. This association was also evident (P=4.9×10 −10 ) in a joint analysis with 2 SNPs rs3798220 and rs10455872 that have been previously shown to be strongly associated with lipoprotein(a) levels 5 ; the LPA null allele was in linkage equilibrium (r2<0.002) with both these SNPs. We then tested the variant for association with CAD risk in 8211 individuals (4022 cases and 4189 controls) and observed a significant protective effect with ≈20% reduction in CAD risk (odds ratio, 0.79; 95% CI, 0.66-0.97; P=0.023) in carriers. 
Correlation of Kringle Isoform Typing Using qPCR and Immunoblotting
Regression Analysis of Lipoprotein(a) Levels
Discussion
Genome-wide and gene-centric association studies have led to the identification of 48 genetic loci associated with CAD risk. The LPA locus on chromosome 6q shows the strongest genetic association with CAD discovered to date. 20, 21 In this study, we have confirmed the effect of a common LPA null allele on circulating lipoprotein(a) levels and shown for the first time a clear association with decreased CAD risk.
We and others have previously mapped quantitative trait loci for lipoprotein(a) and estimated that the vast majority (74 to >90%) of the total variation in circulating levels was specific to the LPA locus. 7, 22, 23 Several studies sought to identify genetic variation in LPA that explains variation in lipoprotein(a) levels and further define the association with CAD risk beyond the contribution of the well-established copy number variation in the KIV-2 domains. This resulted mainly in identification of SNPs that act as proxy markers of the KIV-2 CNV 5,24 or have no proven functional role. 12, 14, 25 
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The rs41272114 single nucleotide polymorphism resulting in an LPA null allele was previously reported by Ogorelkova et al. 13 The minor allele of this SNP causes disruption of a donor splice site and results in a truncated allelic form of apolipoprotein(a), including only kringle domains 1 to 7 (KIV 1-7). Because of the presumed functional importance of specific kringle domains, mutations and truncations related to these are expected to lead to loss of function. Expression of the alternative spliced transcript from the null allele in HepG2 cells showed that the truncated apolipoprotein(a) molecule is expressed and secreted, but because it lacks the KIV-9 domain it is not possible to covalently link to apolipoprotein B-100 and form a stable lipoprotein(a) particle. 13 This truncated apolipoprotein(a) form was found to be extensively degraded in the plasma of carriers and was not detectable by immunoblotting. 13 A null allele effect was clearly evident in the samples of the PROCARDIS study where we found a clear association between circulating levels and carrier status of rs41272114 with a strong effect on lipoprotein(a) levels per null allele, resulting in a significant reduction of median levels. The wellestablished association of circulating levels and CAD risk prompted us to investigate the effect of the LPA null allele on CAD risk in the entire PROCARDIS collection. As expected, reduced levels of lipoprotein(a) because of the null allele had a significant protective effect against risk of disease. This finding highlights the contribution and importance of the null allele as the only known functional polymorphism other than the CNV in modulating lipoprotein(a) levels and CAD disease risk. It is important to note that the rs41272114 SNP resulting in the LPA null allele is not included in any of the available genome-wide, gene-centric, or exome genotyping arrays. Furthermore, these arrays do not include proxy SNPs in strong linkage disequilibrium (r2<0.6), and rs41272114 is not present in the HapMap2 or HapMap3 imputation training sets that have been widely used to drive genome-wide association studies. The findings presented here emphasize the importance of including the null allele in genotyping strategies to be used in future genetic and epidemiological studies.
It was apparent that null allele carrier status could also supplement and refine genotyping data of lipoprotein(a) isoform size because of the KIV-2 CNV. Agarose gel separation followed by immunoblotting and qPCR are 2 methods routinely used in the past for genotyping the LPA CNV in studies including large number of samples.
Lipoprotein(a) kringle isoform typing using immunoblotting is an expensive and low-throughput method that has limited accuracy. It has, however, the advantage that it can provide protein isoform size information encoded separately by each LPA allele (provided they are secreted at detectable levels). Because of the extensive apolipoprotein(a) gene size polymorphism, homozygotes are expected to be unusual in populations in Hardy-Weinberg equilibrium; a heterozygosity index of 94% was reported among Europeans. 26 In the PROCARDIS study, a double band was observed in only a third of the samples assayed using immunoblotting. Null allele carrier status accounted for ≈12% of the single band immunoblots, with the others probably explained by nonsecreted large isoforms or low assay sensitivity.
A qPCR method using genomic DNA as template has been recently used to overcome the inherent restrictions of immunoblotting and estimate the number of kringle repeats in samples from large epidemiological cohorts. 3, 16 However, the high-throughput merits of speed and low cost of the qPCR method are tempered by the inability to distinguish the relative contributions of each allele because it can be used only for detection of the sum of the numbers of kringle domains. Furthermore, this method cannot identify alleles that do not produce a detectable apolipoprotein(a) molecule because of the steric impediment in secretion from producing cells.
Apolipoprotein(a) isoform information derived from immunoblotting and qPCR was supplemented by null allele carrier status to perform a regression analysis of circulating lipoprotein(a) levels in the PROCARDIS samples. Isoform alleles showed a sigmoid pattern of association with lipoprotein(a) levels, suggesting that there is a threshold effect such that relatively short alleles with ≤21 KIV-2 repeats are readily secreted by hepatocytes. This in vivo result is consistent with and provides detail to the inferences drawn from an in vitro study contrasting the expression of 11 and 22 KIV-2 repeat containing plasmids in HepG2 cells. 9 In conclusion, the LPA null allele has a consistent and substantial effect in reducing circulating lipoprotein(a) levels and reducing CAD risk. Genotyping of the null allele enhances the data obtained by either immunoblotting or qPCR for measuring kringle KIV-2 copy number and significantly improves the characterization of LPA-lipoprotein(a) for quantitative genetic analyses.
Concentration of circulating lipoprotein(a) is an independent heritable factor associated with risk of coronary artery disease. The rs41272114 single nucleotide polymorphism that results in a null allele is not included in any of the widely used commercial high-throughput single nucleotide polymorphism arrays and has not been previously examined in large-scale genetic epidemiological studies. Here, we show the association of this functional single nucleotide polymorphisms with reduced lipoprotein(a) levels and risk of coronary artery disease and highlight its importance for future genetic and epidemiological studies.
Significance
